Abbott Celebrates 'Made in China' Milestone with Launch of Locally Produced Alinity i Analyzer and GLP Automation Line

Currently, the "Healthy China" strategy is being continuously implemented in greater depth. The health needs of the people are increasing, and the in vitro diagnostics industry, which combines the advantages of various laboratory disciplines and scientific and technological innovations, also shoulders particularly important responsibilities and missions in safeguarding the health of the Chinese population.

Against this backdrop, Abbott, as a global leader in the IVD industry, has been deeply committed to its localization strategy for over 30 years, striving to provide Chinese patients with more precise and efficient medical services. In this regard, Chen Ying, Global Vice President of Abbott's Core Diagnostics division, stated: "The official launch of the localization of the Alinity i immunoassay module and the GLP automated assembly line in China is another significant demonstration of Abbott's long-term commitment to the Chinese market and our continuous support for the development of healthcare in China. Abbott’s global technology and quality systems will be fully integrated into our Chinese facilities, ensuring unified global standards in R&D, production, quality, and supply chain management. At the same time, we will respond more quickly to the needs of Chinese users and aim to bring innovative solutions inspired by the insights and demands of Chinese users to the global stage."

△ Abbott Core Diagnostics Global Vice President, Elaine Chen

Abbott Speed: Popularizing High-Quality Medical Services

With the strong support of the Zhejiang Provincial Government, this Alinity i localization project in Hangzhou is the first imported medical device localization project in Hangzhou City. It took only 9 months from official approval to authorization, vividly illustrating the Abbott speed and China speed.

As the production plant for Alinity i, Abbott Diagnostics’ Hangzhou facility is not only Abbott's largest global base for researching, developing, and manufacturing immunochromatographic in vitro diagnostic reagents, but it also covers an extensive product line, with an annual market supply of approximately 500 million tests, delivering products to over 100 countries and regions worldwide. Abbott Diagnostics’ Hangzhou facility has also been awarded the title of Zhejiang Provincial Enterprise Technology Center, fully demonstrating its comprehensive strength in operation management, production quality, and innovative research and development.

△ Abbott Diagnostics Hangzhou Factory

At the same time, during the process of achieving "Made in China" for the GLP automated pipeline and the Alinity i immunoassay module, Abbott has also strengthened the resilience, stability, and sustainability of its local supply chain in China. By implementing full industrial chain localization that meets Abbott's global unified standards, it is helping to cultivate new quality productivity in the medical field and promoting the popularization of innovative diagnostic resources and high-quality medical services in China.

Innovative Ecosystem: Commitment to Long-term Development

"A journey of a thousand miles begins with a single step." The rapid advancement of Abbott's localization strategy in China was not achieved overnight but is the result of over 30 years of technical accumulation in the country. Localization of production not only helps improve the speed of response to user needs but also serves as an important way to better understand the actual needs of Chinese patients and provide them with more considerate and convenient medical services. Abbott has evidently made steady progress on its path of local collaboration and innovation.

The China-produced Alinity i is the first product in the Alinity family series of solutions to be launched in China. With features such as more off-instrument time, smaller footprint, higher testing throughput, fewer resource requirements, and faster test reporting, it stands at the forefront of technological innovation, effectively enhancing laboratory operational efficiency and high-quality development. The GLP Laboratory Automation System meets the ever-expanding needs of laboratories by improving sample turnaround time, ensuring accurate clinical decision-making, reducing staff workload, and making full use of space. As an integral part of Abbott's Core Diagnostics integrated, personalized, and intelligent medical laboratory solution, they jointly establish a new standard for laboratories in China.

△ Abbott Diagnostics Immunoassay Module Alinity i and Automated Workflow GLP

In terms of localization, Abbott has established the world's first integrated customer experience center in China — Abbott Innovation Center, as well as three globally leading R&D centers: Abbott Diagnostics R&D Center, Abbott Nutrition R&D Center, and Abbott Rapid Diagnostics R&D Center. Abbott is committed to promoting local innovation and medical transformation. Through the Abbott Diagnostics Academy, Abbott collaborates with industry associations and experts to create a customized, empowering, and forward-looking academic exchange platform, enhancing the overall professional capabilities of medical talents. Relying on the Abbott Translational Science Academy, Abbott builds a collaborative platform for government, industry, academia, research, and medicine, bridging clinical and industrial communication, empowering the cultivation of interdisciplinary technical talents, and promoting the creation of a local innovation ecosystem. Abbott strives to bring innovative achievements driven by the needs and insights of Chinese users to the global stage, further expanding its local network and jointly advancing the high-quality development of China’s healthcare industry.

Setting Sail on a New Journey, Continuously Supporting Health Strategies

Against the backdrop of growing healthcare demands, the localization strategies of global in vitro diagnostic companies are not only crucial for integrating into the Chinese market and achieving sustainable development, but also driving the vigorous growth of China's domestic health industry.

Since entering China in 1988, Abbott has established a broad presence in the healthcare field. Its product portfolio spans key areas from prevention, diagnosis to treatment and rehabilitation, meeting health needs across the entire lifecycle with diverse and comprehensive solutions, thereby becoming a steadfast force driving the development of China’s healthcare industry. As time has progressed to the present, in response to China’s vast and varied healthcare demands, Abbott has further deepened its commitment to China, fulfilling its long-term promise to this land through localized innovation and R&D.

By integrating its cutting-edge diagnostic solutions, Abbott has launched the "Preventive Healthcare for the Future" initiative, creating an industry-leading disease risk assessment model tailored to the needs of the Chinese market. This provides forward-looking health risk evaluations and comprehensive medical guidance. Through the "Greater Preventive Healthcare" public health education program, Abbott promotes the adoption of healthier lifestyles for both individuals and communities.

We believe that in the future, Abbott will continue to advance the development of laboratory medicine with cutting-edge technology and innovative products on its journey of "Deepening Roots in China, Building a Smarter Future," supporting the implementation of the "Healthy China" strategy and bringing health benefits to more people.